Hims & Hers Health reported a sharp acceleration in its international business during the second quarter of 2026 as the telehealth company expands globally and increases its use of AI throughout its healthcare platform.
International revenue reached $131.4 million in Q2, compared with $7.5 million a year earlier, an increase of 1,641%. The international expansion was strengthened by the closing of the Eucalyptus acquisition in June. U.S. revenue increased 16% to $621.8 million.
Total revenue increased 38% to $753.2 million, while subscribers grew 19% to nearly 2.9 million. Monthly revenue per average subscriber increased 21% to $92. Hims & Hers raised full-year revenue guidance to between $3.1 billion and $3.3 billion.
Management is also positioning AI as a central piece of its healthcare model. CEO Andrew Dudum described Hims & Hers as rebuilding the consumer health experience around a doctor-led AI clinical engine. CFO Yemi Okupe said investments in AI and technology are generating efficiencies that could help make more comprehensive care affordable while supporting broader international expansion.
The growth is being accompanied by near-term margin pressure. Gross margin declined to 64% from 76% a year ago, adjusted EBITDA fell to $60.3 million from $82.2 million, and the company recorded a net loss of $86.3 million.
KEY QUOTES:
“As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater.”
Andrew Dudum, Co-Founder and CEO of Hims & Hers
“Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June.”
Yemi Okupe, CFO of Hims & Hers
